对于阿尔茨海默氏病的被动免疫疗法
Xiaoyi Guo1, Li Yan2, Denghong Zhang1
1Center for Brain Sciences, the First Affiliated Hospital of Xiamen University, Institute of Neuroscience, Fujian Provincial Key Laboratory of Neurodegenerative Disease and Aging Research, School of Medicine, Xiamen University, Xiamen, Fujian 361005, China.
Ageing research reviews
|January 14, 2024
概括
使用单克隆抗体 (mAbs) 的被动免疫疗法对阿尔茨海默氏病 (AD) 治疗有希望. 最近的试验强调了抗粉样β (Aβ) 和抗tau mAbs在改善认知和清除AD病理方面的有效性.
科学领域:
- 神经科学是一个神经科学.
- 免疫学 免疫学 免疫学
- 药理学 药理学 是一个学科.
背景情况:
- 阿尔茨海默病 (AD) 是神经退行的主要原因,治疗选择有限.
- 尽管过去有许多失败,但最近被动免疫疗法的进展为AD提供了新的治疗途径.
- 阿尔茨海默病的主要病理特征包括粉样β (Aβ) 斑块,团和神经炎症.
研究的目的:
- 审查AD治疗中单克隆抗体 (mAbs) 的特征,临床试验数据和作用机制.
- 为了评估抗粉样β (Aβ) mAbs,如lecanemab和donanemab的疗效和副作用.
- 探索针对TAU或神经炎症调节器的mAbs在AD中的治疗潜力.
主要方法:
- 对针对Aβ,tau和神经炎症的mAbs进行临床试验数据的审查.
- 对各种免疫疗法剂的作用机制的分析.
- 从III期临床试验中评估疗效和安全性概况.
主要成果:
- 在第三阶段试验中,莱卡尼马布和多纳尼马布在改善AD患者的认知和清除粉样质斑块方面表现出显著的疗效.
- 讨论了影响抗Aβ mAbs疗效和副作用的因素.
- 针对中部区域或致病性tau的mAbs以及炎症调节剂显示出治疗潜力.
结论:
- 针对AD病变发生的关键参与者的被动免疫疗法是有效AD治疗的有希望的策略.
- 单克隆抗体提供了一种可行的方法来解决认知衰退和阿尔茨海默病的病理特征.
- 对定位和抗炎mAbs的进一步研究可能会为AD提供额外的治疗选择.
相关概念视频
01:22Alzheimer's Disease: Treatment
195
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
195
01:26Alzheimer's Disease: Overview
490
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
490
01:31Active versus Passive Immunity
649
Immunity, along with the ability to limit pathogen growth to prevent significant body tissue damage, can be gained either by (1) actively developing an immune response within the individual after exposure to a pathogen or after getting vaccinated or (2) passively transferring immune components from an immune individual to one who is nonimmune. Both these forms of immunity can be found naturally and in medical practices.
Active Immunity
Active immunity refers to the resistance one develops...
Active Immunity
Active immunity refers to the resistance one develops...
649
01:20Myasthenia Gravis: Overview and Treatment
1.5K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.5K